We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| AIM ImmunoTech Inc | AMEX:AIM | AMEX | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.0138 | 3.41% | 0.418 | 0.4198 | 0.3903 | 0.4198 | 48,518 | 23:34:58 |
From May 2022 to May 2024
As part of the virtual event, Thomas K. Equels, MS JD, Chief Executive Officer of AIM ImmunoTech, will be joined by Key Opinion Leaders Dr. Charles Lapp of Hunter-Hopkins Center in Charlotte, N.C. and Dr. Daniel Peterson of Sierra Internal Medicine in Incline Village, Nev. to discuss the Company’s ongoing FDA-authorized treatment protocol (Expanded Access Program) for its investigational drug, Ampligen, which extends to the use and evaluation of the drug in patients with symptoms of “long COVID”.
In addition to the moderated portion of the event, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible during the event.
A live video webcast of the Virtual Investor Long COVID Event will be available on the Events & Presentations page of the Investor Relations section of the Company’s website (aimimmuno.com). A webcast replay will be available two hours following the live presentation and archived for 90 days.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19. The Company’s lead product, Ampligen® (rintatolimod) is an immuno-modulator with broad spectrum activity being developed for globally important cancers, viral diseases and disorders of the immune system.For more information, please visit aimimmuno.com and connect with the Company on Twitter, LinkedIn, and Facebook.
Investor Relations Contact JTC Team, LLC Jenene Thomas 833-475-8247 AIM@jtcir.com
1 Year AIM ImmunoTech Chart |
1 Month AIM ImmunoTech Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
